Serologic evolution of neurocysticercosis patients after antiparasitic therapy

H. H. Garcia, R. H. Gilman, M. Catacora, M. Verastegui, A. E. Gonzalez, V. C.W. Tsang, M. Martinez, J. Altamirano, L. Trelles, J. M. Cuba, M. Alvarado, G. Alban, H. Estrada, N. Rios-Saavedra, M. Soto, M. P. Torres, J. Boero, C. Gavidia, E. Barron

Research output: Contribution to journalArticle

69 Scopus citations

Abstract

Neurocysticercosis is the main cause of acquired epilepsy in developing countries and is an emerging disease in the United States. Introduction of the immunoblot assay provided a new tool for the diagnosis and monitoring of neurocysticercosis. This study analyzed the relationship between clinical characteristics of cerebral infection (number and type of lesions) plus the baseline response on immunoblot and the changes observed after therapy. Reaction to all 7 diagnostic bands was associated with severe infection (more lesions). Seventeen patients (35%) had no active lesions on computed tomography (CT) 3 months after therapy and were considered cured. Although most cured patients remained seropositive after 1 year, 3 became seronegative before 9 months. In these 3 cases, the lesions had resolved on CT at 3 months. Persistent seropositivity does not necessarily indicate active infection. Serologic follow-up will be clinically helpful only in rare cases in which early antibody disappearance occurs.
Original languageAmerican English
Pages (from-to)486-489
Number of pages4
JournalJournal of Infectious Diseases
DOIs
StatePublished - 1 Jan 1997
Externally publishedYes

Fingerprint Dive into the research topics of 'Serologic evolution of neurocysticercosis patients after antiparasitic therapy'. Together they form a unique fingerprint.

  • Cite this

    Garcia, H. H., Gilman, R. H., Catacora, M., Verastegui, M., Gonzalez, A. E., Tsang, V. C. W., Martinez, M., Altamirano, J., Trelles, L., Cuba, J. M., Alvarado, M., Alban, G., Estrada, H., Rios-Saavedra, N., Soto, M., Torres, M. P., Boero, J., Gavidia, C., & Barron, E. (1997). Serologic evolution of neurocysticercosis patients after antiparasitic therapy. Journal of Infectious Diseases, 486-489. https://doi.org/10.1093/infdis/175.2.486